|
|
|
|
|
14.07.26 - 04:30
|
Alert: PHARMARON Expects Interim Net Profit to Rise Up to 10% YoY (AAStocks)
|
|
|
PHARMARON (03759.HK) issued a positive profit alert, expecting interim revenue for the period ended end-Jun this year to reach approximately RMB7.472 billion to RMB7.665 billion, up 16% to 19% YoY. Net profit is expected to be approximately RMB729 million to RMB772 million, up 4% to 10% YoY. Net profit after deducting non-recurr......
|
|
|
|
|
|
|
13.07.26 - 15:01
|
Invesco Ltd: Form 8.3 - Advanced Medical Solutions Group Plc; Public dealing disclosure (Cision)
|
|
|
FORM 8.3
PUBLIC DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)
1. KEY
INFORMATION
(a) Full name of Invesco Ltd.
discloser:
(b) Owner or
controller of
interests and
short
positions
disclosed, if
different
from 1(a):
The naming of
nominee or
vehicle
companies is
insufficient.
For a trust,
the
trustee(s),
settlor and...
|
|
|
|
|
13.07.26 - 11:48
|
Takeda and Indonesia partner on plasma-derived therapies (PBR)
|
|
|
The Ministry of Health of the Republic of Indonesia (BKPM) has issued a fractionation licence to Takeda, allowing the company to collect and process plasma as part of
The post Takeda and Indonesia partner on plasma-derived therapies appeared first on Pharmaceutical Business review....
|
|
|
|
|
13.07.26 - 11:00
|
ZHAOKE OPHTH-B Acquires Global Rights to Atropine Sulfate Eye Drops (AAStocks)
|
|
|
ZHAOKE OPHTH-B (06622.HK) announced that on 22 June, the company acquired the global rights to NVK002 (atropine sulfate eye drops), a drug intended to slow the progression of myopia in children. Under the terms of the agreement, the company will obtain global ownership of all intellectual property, trademarks, regulatory filings......
|
|
|
|
|
|
|
13.07.26 - 06:30
|
ANTENGENE-B Receives USD60 million Upfront Payment from UCB (AAStocks)
|
|
|
ANTENGENE-B (06996.HK) announced that, under the global exclusive licensing agreement reached with UCB for the CD19/CD3 bispecific T-cell engager (TCE) antibody ATG-201, it has received the first upfront payment of USD60 million from the company. The company expects the payment to further strengthen the group's cash position, pr......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
